VectorY Therapeutics announced an €74.5 million ($83.5 million) Series A to fund antibody gene therapy programs aimed at neurodegenerative diseases. The company’s lead asset, VTx-002, is designed to enable antibody production within the brain, addressing a common barrier in neurodegeneration drug delivery—getting biologics to target tissue effectively. The financing highlights continued investor appetite for in vivo or CNS-directed gene platforms and positions VectorY to move beyond preclinical characterization toward later translational milestones.